<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="55872"><DrugName>caspase inhibitors (neonatal brain injury), Chiesi</DrugName><DrugSynonyms><Name><Value>TRP6-01</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>brain ischemia therapeutic, Theraptosis</Value></Name><Name><Value>caspase inhibitors (neonatal brain injury), Chiesi</Value></Name></DrugSynonyms><CompanyOriginator id="29054">Theraptosis</CompanyOriginator><CompaniesPrimary><Company id="15381">Chiesi Farmaceutici SpA</Company></CompaniesPrimary><CompaniesSecondary><Company id="29054">Theraptosis</Company></CompaniesSecondary><CrossReferences><SourceEntity id="55872" type="Drug"><TargetEntity id="412970" type="siDrug">TRP-601</TargetEntity></SourceEntity><SourceEntity id="15381" type="Company"><TargetEntity id="4296558863" type="organizationId">Chiesi Farmaceutici SpA</TargetEntity></SourceEntity><SourceEntity id="29054" type="Company"><TargetEntity id="4296980734" type="organizationId">Theraptosis SA</TargetEntity></SourceEntity><SourceEntity id="1635" type="ciIndication"><TargetEntity id="D020925" type="MeSH"/></SourceEntity><SourceEntity id="1636" type="ciIndication"><TargetEntity id="I67.82" type="ICD10"/><TargetEntity id="D002545" type="MeSH"/><TargetEntity id="-137109010" type="omicsDisease"/><TargetEntity id="91" type="siCondition"/></SourceEntity><SourceEntity id="834" type="ciIndication"><TargetEntity id="10067967" type="MEDDRA"/><TargetEntity id="D001930" type="MeSH"/><TargetEntity id="-564913240" type="omicsDisease"/><TargetEntity id="2453" type="siCondition"/></SourceEntity><SourceEntity id="1590" type="Action"><TargetEntity id="1063" type="Mechanism">Apoptosis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7299" type="Action"><TargetEntity id="1074" type="Mechanism">Caspase 2 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00325" type="ciTarget"><TargetEntity id="9127520398353" type="siTarget">Caspase-2</TargetEntity><TargetEntity id="2216" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="834">Brain injury</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1635">Brain hypoxia-ischemia</Indication><Indication id="1636">Brain ischemia</Indication></IndicationsSecondary><ActionsPrimary><Action id="7299">Caspase-2 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1590">Apoptosis inhibitor</Action><Action id="1615">Neuroprotectant</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2019-05-31T05:59:55.000Z</LastModificationDate><ChangeDateLast>2018-01-17T00:00:00.000Z</ChangeDateLast><AddedDate>2006-08-08T12:27:43.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15381" linkType="Company"&gt;Chiesi&lt;/ulink&gt;, following acquisition from &lt;ulink linkID="29054" linkType="Company"&gt;Theraptosis&lt;/ulink&gt;, is investigating caspase inhibitors for the potential iv treatment of neonatal brain injury [&lt;ulink linkID="1184838" linkType="Reference"&gt;1184838&lt;/ulink&gt;], [&lt;ulink linkID="1185757" linkType="Reference"&gt;1185757&lt;/ulink&gt;], [&lt;ulink linkID="1223072" linkType="Reference"&gt;1223072&lt;/ulink&gt;]. By September 2011, Chiesi had prepared a development plan for a preclinical caspase inhibitor [&lt;ulink linkID="1223072" linkType="Reference"&gt;1223072&lt;/ulink&gt;]. In February 2015, development was ongoing [&lt;ulink linkID="1634185" linkType="Reference"&gt;1634185&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="29054" linkType="Company"&gt;Theraptosis&lt;/ulink&gt; was previously investigating TRP6-01, a neuroprotectant caspase 2 inhibitor, for the potential treatment of cerebral ischemia in the newborn and perinatal hypoxic-ischemic encephalopathy. In August 2006, clinical trials for cerebral ischemia in the newborn were expected to begin  in 2007 [&lt;ulink linkID="682487" linkType="Reference"&gt;682487&lt;/ulink&gt;]. In October 2009, positive preclinical results were reported  [&lt;ulink linkID="1046022" linkType="Reference"&gt;1046022&lt;/ulink&gt;], [&lt;ulink linkID="1050304" linkType="Reference"&gt;1050304&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By September 2006, a Theraptosis compound (structure shown) had been given a positive opinion for Orphan drug status for neonatal brain injury by the EMEA [&lt;ulink linkID="689888" linkType="Reference"&gt;689888&lt;/ulink&gt;]. In February 2010, the Orphan designation was transferred to Chiesi [&lt;ulink linkID="1191515" linkType="Reference"&gt;1191515&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2009, preclinical data were presented for TRP6-01 at the 39th SFN meeting in Chicago, IL. TRP6-01 was evaluated for neuroprotective properties in a neonatal rat model of hypoxia-ischemia (HI) with or without hypothermia. The compound reduced infarction, tissue loss and white matter injury compared with the vehicle. Grey matter injury was also attenuated [&lt;ulink linkID="1046022" linkType="Reference"&gt;1046022&lt;/ulink&gt;], [&lt;ulink linkID="1050304" linkType="Reference"&gt;1050304&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In December 2005, results from preclinical  studies showed that a single 5 mg/kg ip dose of TRP6-01, administered to rat pups before permanent occlusion of the middle cerebral artery and subsequent transient unilateral  carotid ligation, significantly reduced infarct volume compared with control. A significant reduction was also seen when TRP6-01  was administered 1 h after ischemic onset. The drug also did not demonstrate any side effects related to blood flow, blood pressure, cardiac function, blood gazes, temperature and body weight [&lt;ulink linkID="928116" linkType="Reference"&gt;928116&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Between May 2004 and November 2005, Theraptosis filed &lt;ulink linkID="PA2919583" linkType="Patent"&gt;WO-2004103389&lt;/ulink&gt;, &lt;ulink linkID="PA3058978" linkType="Patent"&gt;WO-2005105829&lt;/ulink&gt; and &lt;ulink linkID="PA3200754" linkType="Patent"&gt;WO-2006056487&lt;/ulink&gt; claiming a series of caspase-2 and dual caspase-2/caspase-6 inhibitors for the potential treatment and prevention of various types of ischemia. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="834">Brain injury</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1184838" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29054">Theraptosis</Company><Country id="FR">France</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1636">Brain ischemia</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1184838" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29054">Theraptosis</Company><Country id="FR">France</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1635">Brain hypoxia-ischemia</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1184838" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29054">Theraptosis</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1635">Brain hypoxia-ischemia</Indication><StatusDate>2005-12-31T00:00:00.000Z</StatusDate><Source id="928116" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29054">Theraptosis</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1636">Brain ischemia</Indication><StatusDate>2005-12-31T00:00:00.000Z</StatusDate><Source id="928116" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15381">Chiesi Farmaceutici SpA</OwnerCompany><Country id="EU">EU</Country><Indication id="834">Brain injury</Indication><AwardedIndication>Treatment of neonatal brain injury</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate>2015-04-13T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15381">Chiesi Farmaceutici SpA</OwnerCompany><Country id="EU">EU</Country><Indication id="834">Brain injury</Indication><AwardedIndication>Treatment of neonatal brain injury</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2010-02-28T00:00:00.000Z</MileStoneDate><Source id="1191515" type="OTHER"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15381">Chiesi Farmaceutici SpA</OwnerCompany><Country id="EU">EU</Country><Indication id="834">Brain injury</Indication><AwardedIndication>Treatment of neonatal brain injury</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2006-10-23T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15381">Chiesi Farmaceutici SpA</OwnerCompany><Country id="EU">EU</Country><Indication id="834">Brain injury</Indication><AwardedIndication>Treatment of neonatal brain injury</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2006-09-06T00:00:00.000Z</MileStoneDate><Source id="689888" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00325"><Name>Caspase-2</Name><SwissprotNumbers><Swissprot>P29594</Swissprot><Swissprot>P42575</Swissprot><Swissprot>P55215</Swissprot><Swissprot>Q98943</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15381">Chiesi Farmaceutici SpA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17237">Institut Pasteur</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@H](C(=O)NC(CC(=O)OC)C(=O)COc1c(cccc1F)F)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)OC)NC(=O)[C@H](C(C)C)NC(=O)c2ccc3ccccc3n2</Smiles></StructureSmiles><Deals><Deal id="141453" title="Chiesi Farmaceutici to acquire rights to Theraptosis' phase I product to treat hypoxic-ischemic encephalopathy and perinatal stroke in infants "/></Deals><PatentFamilies><PatentFamily id="1465662" number="WO-2009001322" title="Use of peptide derivatives for treating pathologies resulting from ischemia"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chiesi Farmaceutici SpA" id="15381"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="INSERM" id="17229"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institut Pasteur" id="17237"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>